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Poster Session I S227severe opportunistic infections, a major cause of transplant related
mortality (Lang/ Handgretinger, BMT, 2008). We sought to deter-
mine engraftment, survival, IR, infection risk and frequency of
PTLD andGVHD in pediatrics recipients following CD34-selected
MUD PBSCT.
Methods:Pts# 30 yrs requiring aMUD transplant for selectivema-
lignant and nonmalignant disease who were eligible. HLA matching
included 8/10, 9/10 and 10/10 at intermediate resolutionHLAA and
B and high resolution HLA C, DRB1 and D2. Isolex 300i (Nexell,
Irvine, CA) immunomagnetic cell selection system was used for
CD34 selection with a goal of achieving $ 5 x106 CD34/kg
PBSC. T cells were added back to reach a total CD3 dose of
1.0-2.6x105/kg. GVHD prophylaxis consisted only of tacrolimus
(Bhatia/Cairo et al, BBMT, 2010). Supportive care was as we have
previously described (Bradley/Cairo, BMT, 2007).
Results: 19 pts, median f/u: 534d, median age: 15.3 yrs (10-23); 12:7
M:F, HLAmatch 26% 10/10, 31% 9/10, 42% 8/10; 68%malignant.
Infused grafts contained amedian of 1.6x105CD31/kg (0.1-4.8) and
5.1x106CD341/kg (2.0-13.3). Probabilities of neutrophil and plate-
let engraftment, grade II-IV aGVHD, cGVHD and day 100 TRM
were 100%, 82.3%, 15.8%, 24.2% and 0%, respectively. CD3,
CD4, CD8, CD19 and CD56 counts at day1180/365 reached nor-
mal in 11/30, 0/15, 22/46, 56/76 and 94/100% of patients, respec-
tively. IgG, IgM, and IgA reached normal in 47/50, 59/50, and 59/
33% of patients, respectively. One pt (5.2%) developed PTLD. 11
donor/pts were CMV positive, and 2 pts experienced CMV SVI.
The 1-yr probability of developing SVI and IFI was 42.3% and
28.0%, respectively. Despite the high incidence of SVI and IFI,
the 1-yr probability of mortality due to SVI and IFI was 5.3%
(CI95: 0-65%) and of OS was 84.2% (CI95: 59-95).
Conclusions: Rapid neutrophil engraftment, low rate of PTLD,
aGVHD/ cGVHD, and low day 100 TRMwere observed. Although
immune reconstitution was not mature at 1 yr post transplant, the
overall probability of infection related mortality was relatively low.
These results support continued investigation of CD34-selected
MUD PBSCT in selective pediatric AlloSCT recipients.201
HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR MINORITIES
Ciurea, S.O., Saliba, R.M., Rondon, G., Sharma, M., Montes, N.,
Bosque, D., McMannis, J., Fernandez-Vina, M., Xie, S.,
Konopleva, M., Parmar, S., Nieto, Y., Kebriaei, P., Quazilbash, M.,
Alousi, A., Popat, U., Hosing, C.M., Shpall, E.J., Khouri, I.F., de
Lima, M., Champlin, R.E. The University of TexasMDAnderson Cancer
Center, Houston, TX
Hematopoietic stem cell transplants have been performed mostly
from matched related or unrelated donors (MUD). Given the racial
composition of the unrelated donor registries, it has been difficult
to identify a MUD for non-Caucasian patients (pts). A review of all
the MUD pts transplanted at MD Anderson (MDACC) past 25
years revealed that of 2117 pts, 1677 (79.2%) were whites (W),
271 pts (12.8%) Hispanics (H), 109 (5%) Afican-Americans (AA)
and 33 (1.5%) were Asians (A). Similar racial distribution was noted
with pts receiving a 9/10 MUD during the same period of time.
We hypothesized that haploidentical stem cell transplantation
(HaploSCT) would be an alternative for the minorities without
a matched donor and treated 24 consecutive pts with a conditioning
regimen consisting of fludarabine (40mg/m2/day  4), melphalan
(140mg/m2) and thiotepa (10mg/kg). 4 pts . 55 years/comorbid-
ities received a RIC with fludarabine and lower doses of melphalan
(100mg/m2) and thiotepa (5mg/kg). GVHD prophylaxis consisted
of post transplant cyclophosphamide (50mg/kg/day  2), tacroli-
mus and mycophenolate.
Results: Racial distribution in this group was 8/24 (33.3%) W, 6/
24 (25%) H, 5/24 (21%) AA, 4/24 (16.6%) A, 1/24 (4%) other, for
a total of 66.6% minority population. Median age was 47 years (24-
65). All pts but one received bone marrow stem cells. 4 pts had
prior allogeneic transplants. 13 pts had AML/MDS (8 poor-risk cy-
togenetics), 6 pts had CML/MPD (5/5 blast phase CML), 5 pts had
lymphoma/CLL. Donor-recipient HLA matching was: 5/10 in 12
pts (50%), 6/10 in 3/25 pts (12%), 7/10 in 5/25 pts (20%) and 8/
10 in 4/25 (16%). 10 pts (42%) were in remission at the time of
transplant. All 23 evaluable pts (one had early death) engraftedwith 100% donor chimerism (100% engraftment) after a median
of 19 days (5-40). Cumulative incidence of day-100 treatment-re-
lated mortality (TRM) was 14%. No patients less than 50 years
died of TRM. Grade II-IV aGVHD occurred in 4 patients and
cGVHD in 1 patient. 7/18 (39%) pts relapsed while only 1 for
the pts in remission at the time of transplant. After a median fol-
low-up of 6 months (range 3-18) for survivors of . 100 days
(N 5 14), OS for the whole group was 80%, while PFS for pts
in remission at the time of transplant was 89% (N 5 10, CI
43-98%). No differences in OS/PFS were noted between the
Caucasian and non-Caucasian population.
Conclusion: HaploSCT is a feasible and safe transplant alternative
for minority pts who lack a matched donor.202
HLA-HAPLOIDENTICAL ALLOGENEIC HEMATOPOIETIC STEM CELL
TRANSPLANTATION USING DEPLETION OF CD36CD19 IN CHILDREN
AND ADOLESCENTS: EXPERIENCE AT A SINGLE INSTITUTION
Im, H.J., Park, M., Koh, K.N., Kim, B.E., Choi, E.S., Seo, J.J. Asan
Medical Center Children’s Hospital, Seoul, Republic of Korea
Objective:Toevaluate the safety and efficacy of haploidenticalHCT
(h-HCT) with T-cell depleted graft in children and adolescents
Patients and methods: Between July 2008 and April 2010, 11 pa-
tients received allogeneic PBSCT from mismatched family donors.
Of 11 patients, 6 had SAA (5 acquired, 1 Fanconi anemia), and
5 had hematologic malignancy (HM), of which 3 were AML (1
CR2, 1 refractory, 1 graft failure after CBT), 1 was ALL in CR3,
and 1 was MDS-RA. A total of 13 h-HSCTs were performed in
11 patients. All 13 cases were conditioned with non-myeloablative
regimen containing fludarabine, and busulfan at a dose of 8mg/kg
was added for hematologic malignancies. ATG was also included
except for cases of graft failure and none of enrolled patients re-
ceived any kind of irradiation. The mobilized and collected product
was processed for CD3 alone or CD3/CD19 depletion using
CliniMACS.
Results:Of 11 patients, 9 achieved neutrophil engraftment at a me-
dian of 11 days of whom 2 experienced late graft failure (GF) on
day 125 and 1200, respectively. Four patients developed acute
GVHD of grade II and none had . II aGVHD. Of 4 patients
who experienced GF (2 primary and 2 late), 2 received the 2nd
h-HCT from different donors and all 2 are alive with complete do-
nor chimerism. At a median follow-up of 12.2 (5.927.7) months,
all 11 patients are alive. Of 6 patients with SAA, 4 are well and alive
in a complete donor chimerism without transfusion (TF) need, 1
remains on infrequent need of TF with 95% donor chimerism at
day 1221, and 1 received a 2nd h-HCT for primary GF, after
which the patient remains on infrequent need of TF with full donor
chimerism at day 1145. Of 5 patients with HM, 3 patients with
AML are alive in CR at days 1178, 1412, and 1812, respectively,
although 1 of those experienced late graft failure. The remaining 2
patients are alive with disease at days 1334 and 1377, respectively,
of whom 1 with MDS experienced 1 GF and the other with ALL
relapsed at day 1269. Although no infection-related death
occurred, most of the patients had a viral reactivation or disease, in-
cluding PTLD and CMV retinitis.
Conclusions:TheHCT using haploidentical family donors is a fea-
sible option for children with diseases curable with HCT, but lack
a suitable related or unrelated donor. However, graft failure and in-
fection are still obstacles to overcome to improve the outcome of
hHCT in children and adolescents.203
TREOSULFAN-BASED CONDITIONING IS SUFFICIENT TO PROMOTE
ENGRAFTMENT IN CORD BLOOD TRANSPLANTATION
Newell, L.F.1,2, Milano, F.1, Gutman, J.A.3, Riffkin, I.1, Lopez, M.1,
Ziegler, D.1, Nemecek, E.R.4, Delaney, C.1,5 1Fred Hutchinson Cancer
Research Center, Seattle, WA; 2University of Washington School of Med-
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S228 Poster Session IBackground:Cord blood transplantation (CBT) is potentially cura-
tive for patients with hematologic diseases, yet many patients are in-
eligible for conventional myeloablative conditioning due to prior
therapies, age, and co-morbidities. Treosulfan is an alklyating agent
with myeloablative, immunosuppressive, and antineoplastic activity,
with predictable pharmacokinetics and a favorable toxicity profile.
However, there is limited evidence using Treosulfan in the cord
blood transplant setting.
Methods:We investigated the efficacy of Treosulfan-based condi-
tioning prior to CBT in patients unable to tolerate myeloablative
total body irradiation (TBI) but at high risk for relapse, to demon-
strate that Treosulfan/Fludarabine/TBI was sufficient to promote
CB engraftment. Patients received Treosulfan 14 gm/m2 IV days
-6 to -4, Fludarabine 30 mg/m2 IV days -6 to -2, and 200 cGy
TBI day -1. Graft-versus-host disease (GVHD) prophylaxis was
Cyclosporine and MMF. Cumulative incidence (CI) rates were
used to estimate engraftment and relapse, treating death as a com-
peting risk. Kaplan-Meier analysis was used to estimate overall
survival (OS).
Results: 15 patients aged 4-63 years (median 48), with AML (n5 7),
ALL (n5 4), MDS (n5 2), CML (n5 1), and CMML (n5 1) have
been treated, with a median follow-up of 181 days (range 31-415). 9
patients had disease (n5 3) or minimal residual disease (MRD) (n5
6) at time of transplant. 13 patients received double CBT; 7 patients
received 4/6-matched units, 7 received 5/6-matched, and 1 received
6/6-matched units. The CI of neutrophil engraftment was 85.7%
(95% CI: 53.9-96.2), occurring at a median of 22.5 days (IQR
17.5-29). Only 1 patient had primary graft failure. The CI of relapse
was 26.7% (95% CI: 5.9-54); 2 patients developed MRD at days 28
and 80, and one patient relapsed at day 180. Grade II-IV acute
GVHD (aGVHD) developed in 11/15 patients (overall aGVHD
scores 2-3); there were no cases of grade IV aGVHD. There have
been 5 deaths on protocol: 2 from multi-system organ failure at
days 34 and 40, and 3 deaths from relapse.
Conclusions: Treosulfan provides adequate conditioning to pro-
mote engraftment after CBT in a single center analysis of 15 patients,
and provides an alternate preparative regimen for patients unable to
tolerate TBI-based therapy. Conditioning with Treosulfan was
well-tolerated, and can be used with CBT to extend the donor
pool to patients without conventional donors who are ineligible for
other myeloablative regimens.204
ALLOGENEIC STEM CELL TRANSPLANTATION FROM DONORS OTHER
THAN HLA-MATCHED SIBLINGS IN PEDIATRIC PATIENTS: FAMILY BANK
Hamidieh, A.A., Ostadali, M., Jalili, M., Behfar, M., Basirpanah, S.,
Houseini, A., Bakhti, O., Ghavamzadeh, A. TehranUniversity of Medical
Sciences, Tehran, Islamic Republic of Iran
Objective: Allogeneic haematopoietic stem cell transplantation
(HSCT) has been used to treat a variety of diseases including
malignant and nonmalignant diseases. Best choice of a donor is
a sibling matched donor. However, more than 70% of patients
who need a transplant will have not such donors. For the
patients, donors can be found in the extended family of the patient
or in registries of unrelated donors or cord blood banks. The
purpose of this study is to investigate HSCT from other related
donors.
Methods: During January 2008 to September 2010, we searched in
specified members of a family to detected related donor for 210 pa-
tients who lack a sibling donor and their parents’ marriage was con-
sanguineous marriage. High resolution typing for class I and II
alleles was completed for recipient/donor pairs.
Results:The result of search in the extended family was successful in
43 out of 210 of patients (20.4%) who didn’t have HLAmatched sib-
ling donors. Median age was 5 (range: 1-15 year) that 62.8% was
male. 43 patients with major thalassemia (n 5 11), acute leukemia
(n5 10), fanconi anemia (n5 8), severe aplastic anemia (n5 4), pri-
mary immunodeficiency (n 5 4), histocytic disorder (n 5 2), hurlersyndrome (n 5 2) and osteopetrosis (n 5 2) were selected. The
stem cell source was bone marrow in 30 and peripheral blood in
13 patients. The donors were parents (n5 29), grandfather or grand-
mother (n 5 5) and uncle or aunt (n 5 9). All the 43 patients en-
grafted with neutrophils (. 500/micro L) at a median of 14 days.
15 out of 43 patients who engrafted (37.2%) were complicated by
Acute GVHD. Transplantation related mortality occurred in 2
patients (4.6%).
Conclusion: We have a potentially available donor registry (family
bank) in some countries that consanguineous marriage is not forbid-
den, such as Iran and eastern Mediterranean. While many countries
have very limited numbers of donor registries and cord blood banks,
this type of ‘‘Family Bank’’ can be very helpful and important donor
source. Therefore, all of transplant unit especially in these countries
have to evaluate each single patient before searching in unrelated do-
nor registry and cord blood banks in case of patient who are without
matched sibling donor.205
SUCCESSFUL ENGRAFTMENT AND REDUCED EARLY MORTALITY IN
UNRELATED DONOR (UD) CORD BLOOD (CB) STEM CELL TRANSPLANTA-
TION (SCT) USING A PREPARATIVE REGIMEN OF THIOTEPA, FLUDARA-
BINE, MELPHALAN AND RABBIT ANTI-THYMOCYTE GLOBULIN (TFM/
R-ATG) IN OLDER ADULTS WITH A SINGLE UNMANIPULATED CB UNIT
Nath, R.1, Glen, R.1,William,W.1, Jan, C.1, Ramanathan,M.1, Petrillo-
Deluca, L.1, Yu, N.2, Smethers, K.1, Zankar, D.2, Bruce, W.3, Alan, R.1
1UMass Memorial Medical Center, Worcester, MA; 2UMass Memorial
Medical Center, Worcester, MA; 3UMass Memorial Medical Center,
Worcester, MA
Background: UD-CBSCT in adult patients is associated with
a high incidence of graft failure (10-20%) and increased mortality.
Optimal preparative regimen for CBSCT is currently unknown.
Myeloablative regimens in older adults result in high mortality
while nonmyeloablative regimens have increased graft failure. We
report universal engraftment and reduced early mortality in older
adults who underwent single unit CBSCT with TFM/r-atg as pre-
parative regimen.
Materials and Methods: Retrospective analysis was performed on
all patients who underwent single unit UD-CBSCT at the Umass
medical center over a one year period using TFM/r-atg as prepara-
tive regimen.
Results: Nine patients underwent single unit UD-CBSCT from
April 2009 to March 2010. Diagnosis included MDS/AML (6),
CLL (2) and ALL (1). 6/9 patients had persistent disease. The me-
dian age was 62 years (range 44 to 69) and median weight was 98.1
kg (range 52.6 to 109.3). There were 5 males and 4 females. Pre-
parative regimen consisted of thiotepa 10 mg/kg day -7, fludarabine
30 mg/m2 from day -6 to -2, melphalan 110 to 140 mg/m2 day -1
and r-atg 3 mg/kg given over 2 days (day -4, -3). Graft versus host
disease (gvhd) prophylaxis consisted of mycophenolate mofetil (day
-1 to 56) and tacrolimus (level 5-15 ng/ml) starting day -1. HLA
matching in the direction of rejection was 6/6 in 1; 5/6 in 3 and
4/6 in 5 cases. HLA matching in the direction of gvhd was 6/6
in 1; 5/6 in 2 and 4/6 in 6 cases. The median total nucleated cell
(TNC) dose based on pre-cryopreserved sample was 3.11 (range
2.26 to 5.21)  107/kg. Patients were infused a median of 2.6 
107 TNC /kg (range 1.3 to 3.4) and 0.78  105 CD34 cells/kg
(range 0.016 to 1.56)). All 9 patients successfully engrafted. The
median time to neutrophil engraftment was 20 range (13 -38)
days and platelet engraftment was 44 range (34 to 73) days. All pa-
tients achieved full donor chimerism at engraftment. 100 day and
one year survival are 89% (1/9) and 55% (5/9) respectively. Causes
of death include toxicity 2; gvhd 1; relapse 1; and JC virus associ-
ated PML in one patient. Four patients are currently alive and in
complete remission 12, 15, 16 and 18 months post transplant. All
four patients surviving patients were gvhd free and off all systemic
immunosuppressants at one year post transplant.
